THYROCAREBSEThyrocare Technologies LtdHighNeutral
Announced Thu, 7 May · 19:50 IST

Please find attached herewith intimation regarding the Amendments to Memorandum of Association of the Company

Management Changes View source PDF

THYROCARE · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reaction · full curve 14 horizons · vs prior close
+1.3%1-day move
₹472.50
prior close
₹493.00
base price
After-mkt
timing
5m10m15m30m1D2D3D4D5D7D15D1M2M3M
+4.2+5.4+5.2+3.0+1.3-0.1+1.2-0.5-2.4-0.7+10.1+14.2+10.9
Up moveDown movePending
AI summary

Thyrocare Technologies' Board meeting on May 7, 2026 approved multiple items. The Board recommended a final dividend of Rs. 7 per share (total dividend of Rs. 9.33 per share for FY26 including Rs. 7 interim already paid). Two Non-Executive Non-Independent Directors - Mr. Dharmil Nirupam Sheth and Dr. Dhaval Rajesh Shah - resigned citing preoccupation and other commitments. Two new Additional Directors - Mr. Uday Patel Kadam (COO & CBO at API Holdings) and Mr. Gaurav Verma (CBSO at API Holdings/PharmEasy) - were appointed effective May 8, 2026. Statutory auditors were changed to M/s Price Waterhouse Chartered Accountants LLP for a 5-year term. The Board also approved up to Rs. 5.5 crore investment in subsidiary Think Health Diagnostics Private Limited and alterations to the Memorandum of Association to align with Companies Act 2013 and broaden business scope to include wider healthcare and diagnostics activities.

Likely market impact

The resignations and simultaneous appointments suggest board composition changes potentially aligned with API Holdings' consolidation of control. The dividend declaration is positive for shareholders. The MOA amendments signal potential business expansion beyond core diagnostics into healthcare services, digital platforms, and trading of medical equipment.